NeuroMetrix (NURO) stock more than doubled in two days and crashed the market: still not too late to make big bucks

0

For the past two days, NeuroMetrix has just boomed the market and hit one of the highest points of the year. Yesterday the stock rose from $ 4.26 to $ 10. Today it continues to skyrocket: in today’s pre-market, the price is currently at $ 13, which translates to a 30% increase, while overall it has a sensational increase of 205%. What’s the buzz? The company announced yesterday that the Quell device had been granted breakthrough status by the US Food and Drug Administration for the treatment of symptoms of fibromyalgia in adults.

Fibromyalgia is a common form of chronic pain, followed by Fatigue, sleep, cognitive and mood disorders. It affects an estimated 2-6 percent of the US population (5-15 million people) and is diagnosed in people between 30 and 50. The cause of fibromyalgia remains unclear, but scientific studies explain abnormalities in the way the brain processes normal sensations. and pain is key.

Quell is an advanced nerve stimulation device used by 18 U.S. utility models. It is the only wearable neurostimulator that can be used by a specially designed microchip that provides flexible, precise, and powerful nerve stimulation in a form factor the size of a credit card. Quell uses position and motion detection to automatically adjust stimulation for the best patient experience day and night.

Writing for business and financial publishers has become his passion in the last few decades after completing his Masters in Financial Management has completed. Sharing some opinions and predictions with thousands of readers is a chore for him, but he never promises to invest in a stock.

Weekend Staff.

Writing for business and financial publishers has become his passion in the last few decades after completing his Masters in Financial Management. Sharing some opinions and predictions with thousands of readers is a routine chore for him, but he never promises to invest in a stock.

Keywords:

Neurometrix,NASDAQ:NURO,Stock,Food and Drug Administration,Breakthrough therapy,Nasdaq,Fibromyalgia,Transcutaneous electrical nerve stimulation,Neurometrix, NASDAQ:NURO, Stock, Food and Drug Administration, Breakthrough therapy, Nasdaq, Fibromyalgia, Transcutaneous electrical nerve stimulation,,,

QU’EN PENSEZ-VOUS?

[comment]

PUB

Laisser un commentaire, votre avis compte!

[gs-fb-comments] [comment-form]